# SURMOUNT-MMO Trial Explained Evidence & Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption Last UpdatedAugust 5, 2026 What This Article Covers The SURMOUNT-MMO trial represents a shift in how researchers evaluate GLP-1 compounds. Rather than measuring weight loss or glycemic control as primary outcomes, this ongoing tirzepatide trial tracks… Primary References [reporting in The Pharmaceutical Journal](https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss) [Clinical Trials Arena](https://www.clinicaltrialsarena.com/news/eli-lilly-retatrutide-phase-iii-triumph-1-study-results/) Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use. The **SURMOUNT-MMO trial** represents a shift in how researchers evaluate GLP-1 compounds. Rather than measuring weight loss or glycemic control as primary outcomes, this ongoing [tirzepatide](https://portaltowellness.net/shop/tirzepatide-60mg-10-vial-pack/) trial tracks all-cause mortality and major cardiovascular events directly in adults with obesity but without diabetes. Key Takeaways - SURMOUNT-MMO is notable for using mortality as an endpoint rather than just weight loss, a first for this drug class. - Trial population and design context help explain why this result matters more broadly. - Findings are placed alongside retatrutide’s broader Phase 3 program for context. - Regulatory momentum is building, though full approval implications are still developing. ## Why a Mortality Endpoint Changes the Conversation Most GLP-1 trial programs to date have used weight loss percentage, HbA1c, or other surrogate markers as their primary endpoints. SURMOUNT-MMO is designed differently: its primary endpoint is all-cause mortality and major adverse cardiovascular events (MACE), making it one of the first GLP-1 trials to make longevity itself — not a proxy for it — the central outcome measure researchers are watching. ## Trial Population and Design ### Primary Endpoint The trial is tracking all-cause mortality alongside major cardiovascular events such as heart attack and stroke, evaluated over an extended follow-up period consistent with long-horizon cardiovascular outcome trials. ### Population Criteria Enrollment is limited to adults with obesity who do not have type 2 diabetes, a population selection that isolates the effect of [tirzepatide](https://portaltowellness.net/shop/tirzepatide-15mg/) on mortality and cardiovascular risk from the confounding effects of pre-existing diabetes management. ## Context: How Retatrutide’s Phase 3 Program Compares SURMOUNT-MMO sits alongside a busy 2026 readout calendar for competing GLP-1-class compounds. Retatrutide, the triple GIP/GLP-1/glucagon receptor agonist covered in our , has posted several Phase 3 readouts of its own in 2026, though none yet with a mortality endpoint. | Trial | Compound | Population | Primary Endpoint | Status | | --- | --- | --- | --- | --- | | SURMOUNT-MMO | [Tirzepatide](https://portaltowellness.net/shop/tirzepatide-15mg/) | Obesity, non-diabetic | All-cause mortality + MACE | Ongoing | | TRIUMPH-1 | Retatrutide | General obesity (n=2,339) | % weight loss | Complete (May 2026) | | TRIUMPH-4 | Retatrutide | Knee osteoarthritis population | % weight loss | Complete (Dec 2025) | | TRANSCEND-T2D-1 | Retatrutide | Type 2 diabetes (n=537) | HbA1c change + % weight loss | Complete (June 2026) | In head-to-head obesity-population comparisons, retatrutide has posted larger average weight-loss figures (28.3–28.7%) than [tirzepatide](https://portaltowellness.net/research/tirzepatide-research-guide/) (about 22.5%) or semaglutide (about 14.9%), per [reporting in The Pharmaceutical Journal](https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss) . But weight-loss magnitude and mortality benefit are not the same measurement, which is precisely why a dedicated mortality-endpoint trial like SURMOUNT-MMO matters for the research record. ## Regulatory and Research Momentum Retatrutide’s developer is expected to submit an NDA in Q4 2026, according to [Clinical Trials Arena](https://www.clinicaltrialsarena.com/news/eli-lilly-retatrutide-phase-iii-triumph-1-study-results/) , which also reported that 11.3% of the high-dose retatrutide cohort discontinued treatment due to adverse events, versus 4.9% in the placebo group. That safety signal is part of the broader risk-benefit picture researchers will need to weigh as mortality-focused data, like that expected from SURMOUNT-MMO, becomes available across the GLP-1 class. ## Open Questions for Researchers - Will retatrutide or other multi-receptor agonists receive a parallel mortality-outcome trial design? - How should researchers weigh higher adverse-event discontinuation rates against a potential mortality benefit signal? - Does the shift toward hard outcome endpoints reflect the field increasingly treating GLP-1 compounds as longevity-relevant research subjects rather than purely metabolic ones? - What confounding factors — lifestyle change, monitoring frequency, population selection — complicate interpretation of mortality data from trials like SURMOUNT-MMO? *All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.* 📚 Part of our [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) research guide. Available at PTW Tirzepatide — Research-Grade, Research Use Only [Shop Tirzepatide →](https://portaltowellness.net/shop/tirzepatide-60mg/) ### Continue Your Research Related Articles [Wegovy Pill Total Monthly Cost, Explained](https://portaltowellness.net/research/wegovy-pill-total-monthly-cost/) [GLP-1 Prior Authorization Data](https://portaltowellness.net/research/glp-1-prior-authorization-data/) Related Products [PTW Daily Essentials Kit — Creatine, Electrolytes and Magnesium](https://portaltowellness.net/shop/ptw-daily-essentials-kit/) [Semaglutide – 5mg/vial — Research Use Only](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) Related Research Guide [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) Related Category [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/) More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/) --- Source: https://portaltowellness.net/research/surmount-mmo-trial-tirzepatide-mortality/ Research use only. Terms: https://portaltowellness.net/research-use-only/